降压宝系列方药治疗难治性高血压的临床疗效分析  

Clinical efficacy analysis of the Jiangyabao-series prescription on refractory hypertension

作　　者：高丽君[1] 崔伟锋[1] 范军铭[1] 

机构地区：[1]河南省中医药研究院附属医院,河南郑州450004

出　　处：《中医临床研究》2016年第30期34-35,共2页Clinical Journal Of Chinese Medicine

基　　金：国家自然科学基金资助项目(No.69788090);河南省科技攻关项目(162102310063);河南省中医临床学科领军人才(NO.2013-10)

摘　　要：目的:探讨降压宝系列方药对难治性高血压患者血压的作用。方法:62例难治性高血压患者随机分为治疗组和对照组,各31例。对照组采用缬沙坦胶、硝苯地平缓释片、氢氯噻嗪联合治疗。治疗组在对照组的基础上根据辩证的结果采用降压宝系列方药治疗3个月。观察治疗后两组血压达标率;血压水平、体重指数(BMI)、同型半胱氨酸(Hcy)。结果:治疗后两组血压达标率治疗组70.0%高于对照组45.0%(P<0.05);两组比较SBP、DBP、BMI、Hcy均有明显差别(P<0.05)。结论:降压宝系列方药辅助西医常规治疗可以控制难治性高血压的血压水平,提高血压达标率。降压宝治疗难治性高血压可能与降压宝能改善BMI、HCY等心脑血管危险因素有关。Objective： To explore the efficacy of Jiangyabao-series prescription on blood pressure in patients with refractory hypertension. Methods： 62 patients with refractory hypertension were randomly divided into the treatment group and the control groups, with 31 cases in each group. The control group received the combination therapy, including valsartan gum, nifedipine and hydrochlorothiazide. The treatment group was given the Jiangyabao-series prescription on the basis of the treatment of the control group, 3 months formed a course. After treatment, blood pressure compliance rate, blood pressure levels, BMI, HCY of two groups were observed and compared. Results： After treatment, blood pressure compliance rate was 70% in the treatment group, which was higher than that of the control group, 45% （P〈0.05）. SBP, DBP, BMI, HCY in two groups showed significant differences （P〈0.05）. Conclusion： Jiangyabao-series prescription combined with the conventional western medicine could control blood pressure levels of refractory hypertension and improve blood pressure compliance rate, which were related to the improvement of cardiovascular risk factors such as BMI and HCY.

关 键 词：难治性高血压 降压宝系列方药 心血管危险因素 

分 类 号：R255.3[医药卫生—中医内科学]